This weekend’s news reports deal with:
- A new epidemiological database for prostate cancer research
- Phase II trial results for the “vaccine” PSA: 154-163 (155L)
- The degree to which adding hormone therapy to radiotherapy affects outcomes in patients with localized prostate cancer
- The possibility that zoledronic acid could be used just once a year to prevent bone loss and related events in men having androgen deprivation therapy … READ MORE …
Filed under: Drugs in development, Management, Prevention, Treatment | Tagged: epidemiology, hormone therapy, PSA: 154-163 (155L), radiotherapy, zoledronic acid | 5 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 